340962-93-8

Basic information

• Product Name: 1-Boc-4-Morpholin-4-ylMethyl-piperidine
• Synonyms: 1-Boc-4-Morpholin-4-ylMethyl-piperidine
• CAS NO: 340962-93-8
• Molecular Formula: C15H28N2O3
• Molecular Weight: 284.39442
• Mol File: 340962-93-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 373.024°C at 760 mmHg
• Flash Point: 179.399°C
• Appearance: /
• Density: 1.066g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.494
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Boc-4-Morpholin-4-ylMethyl-piperidine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-Morpholin-4-ylMethyl-piperidine(340962-93-8)
• EPA Substance Registry System: 1-Boc-4-Morpholin-4-ylMethyl-piperidine(340962-93-8)

Safety Data

• Hazardous Substances Data: 340962-93-8(Hazardous Substances Data)

Usage

Description

1-Boc-4-Morpholin-4-ylMethyl-piperidine, also known as Boc-protected morpholinylmethylpiperidine, is a chemical compound used in organic synthesis and pharmaceutical research. It is a derivative of piperidine and contains a Boc (tert-butyloxycarbonyl) protecting group and a morpholine substituent. 1-Boc-4-Morpholin-4-ylMethyl-piperidine has potential applications as a building block in the synthesis of various pharmaceuticals and bioactive molecules. It is known for its ability to act as a chiral auxiliary in asymmetric synthesis, as well as a versatile intermediate in the preparation of diverse chemical compounds. The Boc-protected morpholinylmethylpiperidine has gained attention in medicinal chemistry due to its potential use in the development of new drugs targeting various therapeutic areas.

Uses

Used in Pharmaceutical Research:
1-Boc-4-Morpholin-4-ylMethyl-piperidine is used as a building block for the synthesis of various pharmaceuticals and bioactive molecules. Its unique structure allows it to be a versatile intermediate in the preparation of diverse chemical compounds.
Used in Organic Synthesis:
1-Boc-4-Morpholin-4-ylMethyl-piperidine is used as a chiral auxiliary in asymmetric synthesis. Its ability to influence the stereochemistry of reactions makes it a valuable tool in the development of enantioselective synthetic methods.
Used in Medicinal Chemistry:
1-Boc-4-Morpholin-4-ylMethyl-piperidine is used as a potential component in the development of new drugs targeting various therapeutic areas. Its unique properties and reactivity make it a promising candidate for creating novel pharmaceutical agents.

InChI:InChI=1/C15H28N2O3/c1-15(2,3)20-14(18)17-6-4-13(5-7-17)12-16-8-10-19-11-9-16/h13H,4-12H2,1-3H3

Upstream product

• 110-91-8 morpholine 
• 158407-04-6 tert-butyl 4-(bromomethyl)piperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 6457-49-4 4-piperidinemethanol 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 

Downstream Products

• 81310-62-5 4-[(piperidin-4-yl)methyl]morpholine 

Relevant articles and documents

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and in Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-Activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action.

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.